Erratum: Deconstructing the drug development process: The new face of innovation (Clinical Pharmacology and Therapeutics (2010) 87 (356-361) DOI:10.1038/clpt.2009.293);Deconstructing the drug development process: The new face of innovation

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 356-361

  Kaitin, K I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANASTROZOLE; ATORVASTATIN; BEVACIZUMAB; BUPRENORPHINE PLUS NALOXONE; CAPECITABINE; CARVEDILOL; CETUXIMAB; CLOPIDOGREL; DOCETAXEL; ETIRACETAM; FLUDARABINE PHOSPHATE; GEMCITABINE; IRBESARTAN; LAMOTRIGINE; LANSOPRAZOLE; LATANOPROST; MONTELUKAST; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUETIAPINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SUMATRIPTAN SUCCINATE; TAMSULOSIN; TOLTERODINE; TOPIRAMATE; UNINDEXED DRUG; VALACICLOVIR; ZIPRASIDONE; ZOLEDRONIC ACID;

BIOTECHNOLOGY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; REVIEW;

EID: 77149134011     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.287     Document Type: Erratum

References (31)

1. Grabowski, H.G., Vernon, J.M. & DiMasi, J.A. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20(suppl. 3), 11-29 (2002).
2. Resisting NIcE vol.15, no. 45, pp. a1-a11. BioCentury: The Bernstein Report on BioBusiness, 8 October 2007.
3. FDa amendments act, Pub. L. No.110-85, 121 Stat. 823.
4. Jenkins, J. Development of Drugs in the Safety Environment Post FDaaa (american course on Drug Development and Regulatory Sciences, Washington, Dc, 30 September 2009).
5. A tale of two drugs: atrial fbrillation reviews draw focus on RiskMaPS. The Pink Sheet 70, 8 (2008)
6. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, a. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther., this issue.
7. DiMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&D: is biotech diferent? Managerial Decision Econ. 28, 469-479 (2007)
8. Getz, K.A., Wenger, J., campo, R.A., Seguine, E.S. & Kaitin, K.I. Assessing the impact of protocol design changes on Clinical trial performance. Am. J. Ther. 15, 450-457 (2008).
9. DiMasi, J.A. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 69, 297-307 (2001)
10. Lilly sells its Greenfeld, Indiana, operations to covance; expands existing collaboration between the two companies [press release] http://newsroom. lilly.com/ReleaseDetail.cfm?ReleaseID=326599(2008).
11. Kaitin, K.I. (ed.). Fastest Drug Developers consistently Best Peers on Key Performance Metrics, vol.8, no.5 (Boston: Tufts center for the Study of Drug Development Impact Report, September/October 2006).
12. Kaitin, K.I. (ed.). Best R&D Practices of Top Pharma/Biotech Performers, vol.4, no.4. (Boston: Tufts center for the Study of Drug Development R&D Management Report, October 2009).
13. Getz, K. FIPNet: Pharma's New, Sexy, But Not Yet Ready For Prime-Time Model http://www.nxtbook.com/nxtbooks/advanstar/ insideoutsourcing-200911/#/12
14. Lilly Sings A New Tune: Chorus Unit Brings High Eficiency Note to Early R&
15. Lilly sings a new tune: chorus unit brings high eficiency note to early R&D, vol.69, no.009, pp. 26. The Pink Sheet, 26 February 2007.http://www. choruspharma.com/p070226-26.pdf
16. Enlight Biosciences [press release] http://www.enlightbio.com/news/ enlight-biosciences-launched-in-collaboration-with-merck-and-co-inc-pfzer-and- eli-lilly-pharmaceutical-and-academic-luminaries-combine-forces-to-address- innovation-bottleneck-33(2008)
17. The NIh Common Fund. Common Fund Initiatives http://nihroadmap.nih. gov/initiatives.asp
18. Milne, c.P. & Kaitin, K.I. Translational medicine: an engine of change for bringing new technology to community health. Sci. Transl. Med. 1, 5cm5 (2009)http://stm.sciencemag.org/content/1/5/5cm5.full.pdf.
19. Council of the European Union. Regulation setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines http://register.consilium.europa.eu/pdf/en/07/ st15/st15977.en07.pdf (2007).
20. Proteins. EMEA/CHMP/BMWP/14327/2006 http://www.emea.europa.eu/pdfs/human/ biosimilar/1432706enfin.pdf (13 December 2007).
21. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMEA/CHMP/BMWP/42832/2005 http://www.emea.europa.eu/pdfs/human/ biosimilar/4283205en.pdf (22 February 2006).
22. National Institute for Health and Clinical Excellence. Published Technology Appraisals http://www.nice.org.uk/Guidance/TA/ Published. Accessed 28 April 2009.
23. Joint Formulary Committee. British National Formulary, 57th edn. (British Medical Association and Royal Pharmaceutical Society of Great Britain, London, 2009).
24. Scottish Medicines Consortium. Epoetin Zeta (Retacrit) for Treatment of Anaemia Associated with Chronic Renal Failure http://www. scottishmedicines.org. uk/smc/6094.html (2008). Accessed 28 April 2009.
25. Simoens, S. Interchangeability of off-patent medicines: a pharmacoeconomic perspective. Expert Rev. Pharmacoeconomics Outcomes Res. 8, 519-526 (2008).
26. Briggs, A.H. & O'Brien, B.J. The death of cost-minimization analysis? Health Econ. 10, 179-184 (2001).
27. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Comparability of Biotechnology-Derived Medicinal Products After a Change in the Manufacturing Process: Non-Clinical and Clinical Issues. EMEA/ CHMP/BMWP/101695/2006 http:// www.emea.europa.eu/pdfs/human/ biosimilar/10169506enfin.pdf (19 July 2007).
28. Bosmans, J.E., de Bruijne, M.C., van Hout, H.P., Hermens, M.L., Adèr, H.J. & van Tulder, M.W. Practical guidelines for economic evaluations alongside equivalence trials. Value Health 11, 251-258 (2008).
29. Horton, L.R. The European Experience with Follow-on Biologics Legislation. Federal Trade Commission Roundtable on Follow-on Biologic Drugs: Framework for Competition and Continued Innovation http://www.ftc. gov/bc/workshops/hcbio/docs/fob/lhortonlv. pdf (21 November 2008).
30. Ferner, R.E., Hughes, D.A. & Aronson, J.K. NICE and new: appraising innovation. BMJ 340, b5493 (2010).
31. Medicines and Healthcare Products Regulatory Agency and the Commission on Human Medicines. Biosimilar products: what is biosimilar? Drug Safety Update. 1, 8http://www.mhra.gov.uk/Publications/ Safetyguidance/DrugSafetyUpdate/ CON2033917 (2008).